NCT00846742 is a Phase 2 clinical trial of Stanford V Chemotherapy in Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital.

Who is sponsoring NCT00846742?

NCT00846742 is sponsored by St. Jude Children's Research Hospital.

What drugs are being tested in NCT00846742?

Interventions in NCT00846742: Stanford V Chemotherapy, Radiation Therapy.

What condition does NCT00846742 study?

NCT00846742 studies Hodgkin Lymphoma.

Is NCT00846742 still recruiting?

NCT00846742 is currently active, enrolled. Last updated 6 May 2026.

Are results published for NCT00846742?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-05-06 · How we verify

NCT00846742

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma

Active, enrolled Phase 2 Results posted Last updated 6 May 2026

What this trial tests

Phase 2 trial testing Stanford V Chemotherapy in Hodgkin Lymphoma in 88 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 June 2009

Primary endpoint
11 January 2019

1 October 2028

Quick facts

Lead sponsor	St. Jude Children's Research Hospital
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	88
Start date	5 June 2009
Primary completion	11 January 2019
Estimated completion	1 October 2028
Sites	6 locations across United States

Drugs / interventions tested

Stanford V Chemotherapy — full drug profile →
Radiation Therapy — full drug profile →

Conditions studied

Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →

Sponsor

St. Jude Children's Research Hospital

Who can join

Under 21, any sex, with Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Complete Response Rate Estimate
Time frame: 8 weeks
To increase the complete response rate of favorable risk patients (excluding all patients with stage IA nodular lymphocyte predominant Hodgkin lymphoma) after 8 weeks Stanford V by at least 20% compared to favorable risk patients on HOD 99 after 8 weeks VAMP (NCT number: NCT00145600) .Complete response definition: Disappearance of all measurable or evaluable disease, signs, symptoms and biochemica

Sponsor's own description

This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride, vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells for those patients that still had residual cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in paediatric cancer treatment.
Saletta F, Seng MS, Lau LM. · · 2014 · cited 50× · PMID 26835334 · DOI 10.3978/j.issn.2224-4336.2014.02.01
Accelerating pediatric Hodgkin lymphoma research: the Hodgkin Lymphoma Data Collaboration (NODAL).
Wyatt KD, Birz S, Castellino SM, Henderson TO, et al · · 2024 · cited 3× · PMID 38273668 · DOI 10.1093/jnci/djae013
Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08.
Flerlage JE, Feraco AM, Zhou Y, Zheng Y, et al · · 2026 · PMID 41529162 · DOI 10.1182/blood.2025029535
Abstract Book : Topic: 13th International Symposium on Hodgkin Lymphoma; October 2024
· 2024

Verify or expand the search:

Other recruiting trials for Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
NCT07002216 — BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma · Phase 2 · recruiting

Other St. Jude Children's Research Hospital trials

Trials by the same sponsor.

NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
NCT07085338 — A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Pat · Phase 2 · recruiting
NCT05664113 — Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction i · Phase 1 · recruiting
NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
NCT06326463 — CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00846742 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Jude Children's Research Hospital
Last refreshed: 6 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00846742.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing